Abeona Therapeut Financials

ABEO

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Abeona Therapeut (ABEO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Abeona Therapeut passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Abeona Therapeut generates $0.88 in operating cash flow (-$56.0M OCF vs -$63.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-15.3x

Abeona Therapeut earns $-15.3 in operating income for every $1 of interest expense (-$64.2M vs $4.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$62.2M

YoY-38.7%

Abeona Therapeut's EBITDA was -$62.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 38.7% from the prior year.

Free Cash Flow

-$58.5M

YoY-56.6%

Abeona Therapeut generated -$58.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 56.6% from the prior year.

Net Income

-$63.7M

YoY-17.6%

Abeona Therapeut reported -$63.7M in net income in fiscal year 2024. This represents a decrease of 17.6% from the prior year.

EPS (Diluted)

$-1.55

YoY+38.7%

Abeona Therapeut earned $-1.55 per diluted share (EPS) in fiscal year 2024. This represents an increase of 38.7% from the prior year.

Cash & Debt

$23.4M

YoY+61.4%

5Y CAGR-29.0%

10Y CAGR+7.3%

Abeona Therapeut held $23.4M in cash against $13.0M in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

46M

YoY+72.1%

Abeona Therapeut had 46M shares outstanding in fiscal year 2024. This represents an increase of 72.1% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$34.4M

YoY+10.5%

5Y CAGR-6.7%

10Y CAGR+59.0%

Abeona Therapeut invested $34.4M in research and development in fiscal year 2024. This represents an increase of 10.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.4M

YoY+639.0%

5Y CAGR-17.3%

Abeona Therapeut invested $2.4M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 639.0% from the prior year.

ABEO Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	$3.5M+147.5%	$1.4M-52.9%	$3.0M-70.0%	$10.0M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$34.4M+10.5%	$31.1M+7.3%	$29.0M-25.2%	$38.7M+28.5%	$30.1M-37.9%	$48.6M
SG&A Expenses	$29.9M+57.1%	$19.0M+10.1%	$17.3M-20.3%	$21.6M-9.0%	$23.8M+14.8%	$20.7M
Operating Income	-$64.2M-36.2%	-$47.1M+7.4%	-$50.9M+43.3%	-$89.8M-10.3%	-$81.4M-5.6%	-$77.1M
Interest Expense	$4.2M+906.7%	$418K-43.2%	$736K-79.9%	$3.7M-11.2%	$4.1M	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$63.7M-17.6%	-$54.2M-36.5%	-$39.7M+53.3%	-$84.9M-0.8%	-$84.2M-10.4%	-$76.3M
EPS (Diluted)	$-1.55+38.7%	$-2.53+54.2%	$-5.53	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	$400K	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$488K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.2M-29.1%	$5.9M-40.2%	$9.9M+11.2%	$8.9M-3.0%	$9.2M+27.9%	$7.2M	N/A	$7.1M
SG&A Expenses	$19.3M+12.6%	$17.1M+75.2%	$9.8M+52.8%	$6.4M-25.9%	$8.6M+21.4%	$7.1M	N/A	$4.2M
Operating Income	-$24.0M-5.4%	-$22.8M-15.5%	-$19.7M-28.6%	-$15.3M+14.1%	-$17.9M-24.7%	-$14.3M	N/A	-$11.3M
Interest Expense	$901K-5.9%	$957K-4.1%	$998K-9.4%	$1.1M+2.8%	$1.1M+12.6%	$952K	N/A	$105K
Income Tax	-$15.2M-198.0%	$15.5M	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$5.2M-104.7%	$108.8M+1004.8%	-$12.0M+60.3%	-$30.3M-508.7%	$7.4M+123.5%	-$31.6M	N/A	-$11.8M
EPS (Diluted)	$-0.10-105.8%	$1.71+812.5%	$-0.24+61.9%	$-0.63-142.3%	$-0.26+77.6%	$-1.16	N/A	$-0.48

ABEO Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$108.9M+70.2%	$64.0M-0.3%	$64.2M-19.3%	$79.6M-47.4%	$151.2M-32.3%	$223.4M
Current Assets	$100.9M+80.9%	$55.7M+5.0%	$53.1M-5.7%	$56.3M-42.4%	$97.7M-26.2%	$132.4M
Cash & Equivalents	$23.4M+61.4%	$14.5M+1.8%	$14.2M-56.8%	$32.9M+161.5%	$12.6M-90.3%	$129.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$3.0M	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	$32.5M0.0%	$32.5M
Total Liabilities	$64.9M+32.0%	$49.2M+31.3%	$37.5M+0.6%	$37.2M-23.5%	$48.6M+8.2%	$45.0M
Current Liabilities	$16.6M+23.6%	$13.4M+72.5%	$7.8M-53.2%	$16.6M-60.4%	$42.0M+8.4%	$38.7M
Long-Term Debt	$13.0M	N/A	N/A	N/A	N/A	N/A
Total Equity	$44.0M+197.0%	$14.8M-44.6%	$26.8M-36.8%	$42.4M-58.7%	$102.6M-42.5%	$178.4M
Retained Earnings	-$813.3M-8.5%	-$749.5M-7.8%	-$695.3M-6.1%	-$655.6M-14.9%	-$570.7M-17.3%	-$486.5M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$231.1M-6.1%	$246.2M+147.8%	$99.4M-8.8%	$108.9M-18.7%	$134.0M+79.1%	$74.8M+16.9%	$64.0M-3.2%	$66.1M
Current Assets	$216.1M-6.9%	$232.3M+163.6%	$88.1M-12.6%	$100.9M-19.9%	$125.9M+88.7%	$66.7M+19.7%	$55.7M-2.7%	$57.3M
Cash & Equivalents	$82.9M-49.3%	$163.5M+926.2%	$15.9M-31.8%	$23.4M-32.2%	$34.4M+96.1%	$17.6M+21.3%	$14.5M+207.2%	$4.7M
Inventory	$4.8M+80.6%	$2.7M	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$59.9M-27.6%	$82.7M+42.6%	$58.0M-10.7%	$64.9M+6.8%	$60.8M-27.4%	$83.7M+70.2%	$49.2M+11.6%	$44.0M
Current Liabilities	$22.2M-35.7%	$34.5M+91.9%	$18.0M+8.4%	$16.6M-1.5%	$16.8M+41.7%	$11.9M-11.4%	$13.4M+59.6%	$8.4M
Long-Term Debt	$10.9M-22.4%	$14.0M+25.7%	$11.1M-14.6%	$13.0M-19.2%	$16.1M-10.8%	$18.1M	N/A	N/A
Total Equity	$171.2M+4.7%	$163.6M+295.1%	$41.4M-6.0%	$44.0M-39.9%	$73.2M+924.7%	-$8.9M-159.9%	$14.8M-32.7%	$22.0M
Retained Earnings	-$721.6M-0.7%	-$716.5M+13.2%	-$825.3M-1.5%	-$813.3M-5.1%	-$773.7M+0.9%	-$781.1M-4.2%	-$749.5M-2.3%	-$732.9M

ABEO Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$56.0M-51.4%	-$37.0M+14.9%	-$43.5M+33.8%	-$65.7M-87.5%	-$35.0M+44.3%	-$62.8M
Capital Expenditures	$2.4M+639.0%	$331K+154.6%	$130K-96.9%	$4.2M+210.7%	$1.3M-78.8%	$6.3M
Free Cash Flow	-$58.5M-56.6%	-$37.3M+14.4%	-$43.6M+37.5%	-$69.8M-92.0%	-$36.4M+47.4%	-$69.1M
Investing Cash Flow	-$39.2M-18965.4%	$208K+100.9%	-$24.0M-136.3%	$66.1M+178.9%	-$83.7M-239.6%	$60.0M
Financing Cash Flow	$104.1M+181.0%	$37.1M-14.2%	$43.2M+73.7%	$24.9M+1184.1%	$1.9M-98.3%	$113.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$21.2M-12.8%	-$18.8M-2.1%	-$18.4M-11.1%	-$16.6M-30.6%	-$12.7M+12.8%	-$14.5M-57.4%	-$9.2M-60.7%	-$5.7M
Capital Expenditures	$2.5M-13.1%	$2.9M+107.1%	$1.4M+131.2%	$606K-14.8%	$711K-1.9%	$725K+1859.5%	$37K-15.9%	$44K
Free Cash Flow	-$23.7M-9.3%	-$21.7M-9.5%	-$19.8M-15.4%	-$17.2M-28.1%	-$13.4M+12.2%	-$15.3M-64.6%	-$9.3M-60.1%	-$5.8M
Investing Cash Flow	-$64.6M-141.5%	$155.9M+3600.2%	$4.2M-77.7%	$18.9M+142.8%	-$44.1M-464.6%	-$7.8M-167.8%	$11.5M+161.5%	-$18.7M
Financing Cash Flow	$5.2M-50.8%	$10.5M+55.1%	$6.8M+27.4%	$5.3M-92.8%	$73.7M+189.6%	$25.4M+240.7%	$7.5M-67.5%	$23.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ABEO Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-1346.7%+2254.1pp	-3600.8%-606.3pp	-2994.5%-2180.3pp	-814.2%	N/A
Net Margin	N/A	-1548.2%+1259.1pp	-2807.4%+23.8pp	-2831.2%-1988.9pp	-842.3%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-58.5%+26.2pp	-84.7%-22.9pp	-61.8%+44.9pp	-106.7%-51.0pp	-55.7%-21.6pp	-34.2%
Current Ratio	6.08+1.9	4.15-2.7	6.83+3.4	3.39+1.1	2.33-1.1	3.42
Debt-to-Equity	0.30-3.0	3.32+1.9	1.40+0.5	0.88+0.4	0.47+0.2	0.25
FCF Margin	N/A	-1066.9%+2017.5pp	-3084.4%-757.2pp	-2327.2%-1963.6pp	-363.6%	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-5698.0%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	27208.3%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	66.5%	N/A	N/A	10.1%	N/A	N/A	N/A
Return on Assets	-2.2%-46.4pp	44.2%+56.3pp	-12.1%+13.0pp	-25.1%-30.6pp	5.5%+47.7pp	-42.2%	N/A	-17.9%
Current Ratio	9.74+3.0	6.73+1.8	4.90-1.2	6.08-1.4	7.48+1.9	5.61+1.5	4.15-2.7	6.81
Debt-to-Equity	0.06-0.0	0.09-0.2	0.27-0.0	0.30+0.1	0.22+2.3	-2.04-5.4	3.32+1.3	2.00
FCF Margin	N/A	-5421.3%	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

AUTOLUS THERAPEUTICS PLC AUTL

$372.6M

Rocket Pharmaceu RCKT

$353.9M

Tectonic Therapeutic Inc TECX

$417.0M

Immuneering Corp IMRX

$318.3M

Design Therapeutics, Inc. DSGN

$573.6M

Frequently Asked Questions

Is Abeona Therapeut profitable?

No, Abeona Therapeut (ABEO) reported a net income of -$63.7M in fiscal year 2024.

What is Abeona Therapeut's earnings per share (EPS)?

Abeona Therapeut (ABEO) reported diluted earnings per share of $-1.55 for fiscal year 2024. This represents a 38.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Abeona Therapeut's EBITDA?

Abeona Therapeut (ABEO) had EBITDA of -$62.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Abeona Therapeut have?

As of fiscal year 2024, Abeona Therapeut (ABEO) had $23.4M in cash and equivalents against $13.0M in long-term debt.

What is Abeona Therapeut's free cash flow?

Abeona Therapeut (ABEO) generated -$58.5M in free cash flow during fiscal year 2024. This represents a -56.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Abeona Therapeut's operating cash flow?

Abeona Therapeut (ABEO) generated -$56.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Abeona Therapeut's total assets?

Abeona Therapeut (ABEO) had $108.9M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Abeona Therapeut's capital expenditures?

Abeona Therapeut (ABEO) invested $2.4M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Abeona Therapeut spend on research and development?

Abeona Therapeut (ABEO) invested $34.4M in research and development during fiscal year 2024.

How many shares does Abeona Therapeut have outstanding?

Abeona Therapeut (ABEO) had 46M shares outstanding as of fiscal year 2024.

What is Abeona Therapeut's current ratio?

Abeona Therapeut (ABEO) had a current ratio of 6.08 as of fiscal year 2024, which is generally considered healthy.

What is Abeona Therapeut's debt-to-equity ratio?

Abeona Therapeut (ABEO) had a debt-to-equity ratio of 0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Abeona Therapeut's return on assets (ROA)?

Abeona Therapeut (ABEO) had a return on assets of -58.5% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Abeona Therapeut's cash runway?

Based on fiscal year 2024 data, Abeona Therapeut (ABEO) had $23.4M in cash against an annual operating cash burn of $56.0M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Abeona Therapeut's Piotroski F-Score?

Abeona Therapeut (ABEO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Abeona Therapeut's earnings high quality?

Abeona Therapeut (ABEO) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Abeona Therapeut cover its interest payments?

Abeona Therapeut (ABEO) has an interest coverage ratio of -15.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.